ReviewGynecologic oncology research and practice2017
Mechanistic insights into ADXS11-001 human papillomavirus-associated cancer immunotherapy.
Review in Gynecologic oncology research and practice, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- The Use of Bacteria and Their Toxins as Antitumor Agents: Present and Future.Microorganisms · 2026Review
- Advances in immunotherapy for HPV-associated malignancies: emerging strategies and clinical progress.Frontiers in immunology · 2026Review
- HarnessingArchives of Razi Institute · 2025Review
- Targeting archetypes of viral-driven cancers with immunotherapy: a perspective on immunogenicity within the tumor microenvironment.Frontiers in immunology · 2025Review
- Epidemiology, Molecular Pathogenesis, Immuno-Pathogenesis, Immune Escape Mechanisms and Vaccine Evaluation for HPV-Associated Carcinogenesis.Pathogens (Basel, Switzerland) · 2023Review
- Immune Microenvironment and Immunotherapeutic Management in Virus-Associated Digestive System Tumors.International journal of molecular sciences · 2022Review
- Engineered bacteria as drug delivery vehicles: Principles and prospects.Engineering microbiology · 2022Review
- Neoadjuvant Immunotherapy Strategies in HPV-Related Head-and-Neck Cancer.Current otorhinolaryngology reports · 2022Article
- Microbiome engineering: engineered live biotherapeutic products for treating human disease.Frontiers in bioengineering and biotechnology · 2022Review
- Immunotherapy for HPV Malignancies.Seminars in radiation oncology · 2021Review
- ADXS11-001 LM-LLO as specific immunotherapy in cervical cancer.Human vaccines & immunotherapeutics · 2021Article
- Enhanced therapeutic efficacy of Listeria-based cancer vaccine with codon-optimized HPV16 E7.Human vaccines & immunotherapeutics · 2021Article
- Immunotherapy in Cervical Cancer.Current oncology reports · 2021Review
- Vaccination Strategies for the Control and Treatment of HPV Infection and HPV-Associated Cancer.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2021Article
- Article
- Immunotherapy in Anal Cancer.Current oncology reports · 2020Review
- Article
- Vaccine strain Listeria monocytogenes bacteremia occurring 31 months after immunization.Infection · 2019Article
- TA-MUC1 as detected by the fully humanized, therapeutic antibody Gatipotzumab predicts poor prognosis in cervical cancer.Journal of cancer research and clinical oncology · 2018Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune responses to the facultative intracellular bacterium
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.